OncoMatch/Clinical Trials/NCT06342037
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Is NCT06342037 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tiragolumab and Atezolizumab for metastatic breast cancer.
Treatment: Tiragolumab · Atezolizumab · Ipilimumab — This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression <10% (<10%)
Estrogen receptor (ER) negativity (ER <10%)
Required: HER2 (ERBB2) IHC 0, 1+ or 2+ with no amplification (IHC 0, 1+ or 2+ with no amplification)
HER2 negativity (HER2 IHC 0, 1+ or 2+ with no amplification)
Required: PD-L1 (CD274) CPS<10 (CPS<10)
PD-L1 negative disease determined using the Combined Positivity Score (CPS<10) (Dako 22C3 IHC)
Performance status
WHO 0–1
Prior therapy
Must have received: anti-PD-1 therapy — (neo)adjuvant or metastatic
previously treated with anti-PD(L)1 in the (neo)adjuvant or metastatic setting (irrespective of PD-L1 status)
Cannot have received: anti-CTLA-4 therapy
Prior treatment with an anti-CTLA4 antibody
Cannot have received: anti-TIGIT antibody
Prior treatment with an anti-TIGIT antibody
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify